Arrivent Biopharma Inc Financials
This page shows Arrivent Biopharma Inc (AVBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ArriVent’s business model is a research-led cash burn supported by a capital-raising balance-sheet reset, not operating inflows.
Across FY2024-FY2025, financing inflows of$389.6M funded most of operating and investing cash outflows of$494.5M . Even after that support, cash fell from$74.3M to$45.5M as R&D roughly doubled, so the stronger equity base reflects external funding more than internal cash generation.
The cost structure is overwhelmingly research-heavy: FY2025 R&D reached
The balance sheet has been reset by equity funding: total equity moved from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Arrivent Biopharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Arrivent Biopharma Inc carries a low D/E ratio of 0.08, meaning only $0.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 12.83, Arrivent Biopharma Inc holds $12.83 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Arrivent Biopharma Inc generates a -54.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -31.2% the prior year.
Arrivent Biopharma Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Arrivent Biopharma Inc generates $0.97 in operating cash flow (-$160.6M OCF vs -$166.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Arrivent Biopharma Inc's EBITDA was -$180.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Arrivent Biopharma Inc reported -$166.3M in net income in fiscal year 2025. This represents a decrease of 106.6% from the prior year.
Arrivent Biopharma Inc earned $-4.32 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 68.8% from the prior year.
Cash & Balance Sheet
Arrivent Biopharma Inc held $45.5M in cash against $0 in long-term debt as of fiscal year 2025.
Arrivent Biopharma Inc had 42M shares outstanding in fiscal year 2025. This represents an increase of 25.9% from the prior year.
Margins & Returns
Arrivent Biopharma Inc's ROE was -54.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 22.9 percentage points from the prior year.
Capital Allocation
Arrivent Biopharma Inc invested $153.4M in research and development in fiscal year 2025. This represents an increase of 94.1% from the prior year.
AVBP Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $37.6M | N/A | $32.2M+16.0% | $27.7M-54.8% | $61.3M | N/A | $20.1M-7.8% | $21.8M |
| SG&A Expenses | $8.5M | N/A | $6.1M+4.2% | $5.9M+7.7% | $5.5M | N/A | $4.1M+5.7% | $3.9M |
| Operating Income | -$46.1M | N/A | -$38.3M-14.0% | -$33.6M+49.6% | -$66.8M | N/A | -$24.2M+5.7% | -$25.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$43.3M | N/A | -$35.0M-11.4% | -$31.4M+51.2% | -$64.4M | N/A | -$20.6M+6.0% | -$21.9M |
| EPS (Diluted) | $-0.96 | N/A | $-0.83+7.8% | $-0.90+52.6% | $-1.90 | N/A | $-0.61+6.2% | $-0.65 |
AVBP Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $349.3M+4.8% | $333.2M+2.0% | $326.6M+21.2% | $269.5M+25.1% | $215.5M-21.6% | $274.9M-6.1% | $292.7M-5.2% | $308.9M |
| Current Assets | $348.7M+4.7% | $332.9M+3.6% | $321.2M+28.4% | $250.1M+34.6% | $185.8M-18.1% | $227.0M-22.4% | $292.4M-5.2% | $308.5M |
| Cash & Equivalents | $62.1M+36.4% | $45.5M-59.6% | $112.7M-0.1% | $112.8M+126.1% | $49.9M-32.9% | $74.3M-73.7% | $282.9M-5.3% | $298.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $25.3M-2.4% | $25.9M+20.3% | $21.6M+9.8% | $19.6M+51.6% | $13.0M-25.1% | $17.3M+13.6% | $15.2M+24.8% | $12.2M |
| Current Liabilities | $25.0M-3.7% | $25.9M+20.3% | $21.6M+9.8% | $19.6M+51.6% | $13.0M-25.0% | $17.3M+13.9% | $15.2M+25.3% | $12.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $324.0M+5.5% | $307.2M+0.7% | $305.0M+22.1% | $249.9M+23.4% | $202.5M-21.4% | $257.7M-7.1% | $277.5M-6.5% | $296.7M |
| Retained Earnings | -$448.0M-10.7% | -$404.6M-9.6% | -$369.1M-10.5% | -$334.1M-10.4% | -$302.7M-27.0% | -$238.3M-9.5% | -$217.7M-10.4% | -$197.1M |
AVBP Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$41.9M-36.6% | -$30.7M+14.4% | -$35.8M-37.0% | -$26.1M+61.6% | -$68.0M-321.1% | -$16.2M+1.2% | -$16.3M+14.4% | -$19.1M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $3.6M+105.0% | -$71.2M-40.3% | -$50.8M-464.9% | $13.9M-62.2% | $36.8M | N/A | N/A | N/A |
| Financing Cash Flow | $54.9M+58.0% | $34.7M-59.8% | $86.5M+15.1% | $75.1M+1011.3% | $6.8M+12189.1% | $55K-89.6% | $531K+46.3% | $363K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AVBP Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -13.4% | N/A | -11.5%+1.1pp | -12.6%+19.2pp | -31.8% | N/A | -7.4%-0.0pp | -7.4% |
| Return on Assets | -12.4% | N/A | -10.7%+0.9pp | -11.7%+18.2pp | -29.9% | N/A | -7.0%+0.1pp | -7.1% |
| Current Ratio | 13.95+1.1 | 12.83-2.1 | 14.90+2.2 | 12.74-1.6 | 14.34+1.2 | 13.14-6.1 | 19.28-6.2 | 25.50 |
| Debt-to-Equity | 0.080.0 | 0.08+0.0 | 0.070.0 | 0.08+0.0 | 0.060.0 | 0.07+0.0 | 0.05+0.0 | 0.04 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Arrivent Biopharma Inc profitable?
No, Arrivent Biopharma Inc (AVBP) reported a net income of -$166.3M in fiscal year 2025.
What is Arrivent Biopharma Inc's EBITDA?
Arrivent Biopharma Inc (AVBP) had EBITDA of -$180.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Arrivent Biopharma Inc's return on equity (ROE)?
Arrivent Biopharma Inc (AVBP) has a return on equity of -54.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Arrivent Biopharma Inc's operating cash flow?
Arrivent Biopharma Inc (AVBP) generated -$160.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Arrivent Biopharma Inc's total assets?
Arrivent Biopharma Inc (AVBP) had $333.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Arrivent Biopharma Inc spend on research and development?
Arrivent Biopharma Inc (AVBP) invested $153.4M in research and development during fiscal year 2025.
What is Arrivent Biopharma Inc's current ratio?
Arrivent Biopharma Inc (AVBP) had a current ratio of 12.83 as of fiscal year 2025, which is generally considered healthy.
What is Arrivent Biopharma Inc's debt-to-equity ratio?
Arrivent Biopharma Inc (AVBP) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Arrivent Biopharma Inc's return on assets (ROA)?
Arrivent Biopharma Inc (AVBP) had a return on assets of -49.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Arrivent Biopharma Inc's cash runway?
Based on fiscal year 2025 data, Arrivent Biopharma Inc (AVBP) had $45.5M in cash against an annual operating cash burn of $160.6M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Arrivent Biopharma Inc's Piotroski F-Score?
Arrivent Biopharma Inc (AVBP) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Arrivent Biopharma Inc's earnings high quality?
Arrivent Biopharma Inc (AVBP) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Arrivent Biopharma Inc?
Arrivent Biopharma Inc (AVBP) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.